IOS-1002
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IOS-1002, covering 2026-03-27 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors [Phase 1]